Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NovaDigm Wraps Up Second Study

By Drug Discovery Trends Editor | May 14, 2012

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study. The presentation was made at the 15th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Baltimore, MD. NDV-3 is a vaccine being developed for the prevention and treatment of diseases caused by Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 contains recombinant Als3, a surface adhesin/invasin from Candida albicans, which is the first vaccine antigen to demonstrate preclinical “cross-kingdom” protective efficacy against both fungal and bacterial pathogens. Results from the new study demonstrated that a single dose of NDV-3 with or without alum adjuvant was safe, well-tolerated and induced strong antibody and T-cell immune responses.

“The data from our second Phase 1 study confirms positive results from our initial Phase 1 study and shows that those receiving adjuvant-free NDV-3 had robust immune responses, as did those receiving NDV-3 with alum adjuvant,” said Timothy Cooke, Ph.D., NovaDigm’s Chief Executive Officer. “These results position us to begin Phase 2 efficacy studies with an optimized vaccine formulation and a Phase 1 safety database of 200 adults.”

The second Phase 1 trial was a double-blind, placebo-controlled study in 160 healthy adults evaluating the safety, tolerability and immunogenicity of a single dose of three different formulations and two routes of administration. A dose of the vaccine containing 300 µg of Als3 was administered intramuscularly with and without alum adjuvant to assess the impact of the adjuvant. In the third vaccinated group, a dose of NDV-3 containing 30 µg of Als3 was administered intradermally without alum adjuvant.

Results from the study demonstrated the safety and tolerability of NDV-3 in all three vaccinated groups compared to the saline placebo group. All three vaccinated groups showed rapid increases in serum and vaginal immunoglobulin G (IgG) and immunoglobulin A1 (IgA1) antibodies by day 7 following vaccination, which peaked at day 14. The demonstration of vaginal antibody responses to NDV-3 may be important in preventing vaginal yeast infections caused by Candida albicans, which is the objective of a planned Phase 2 efficacy study. The majority of subjects that received NDV-3 also demonstrated significant Als3-stimulated production of the T-cell cytokines IL-17A and IFN-γ between 7 and 14 days post-vaccination relative to subjects receiving placebo.

The Phase 1 data were presented in an oral presentation titled, NDV-3, a Recombinant Vaccine for Candida and Staphylococcus aureus is Safe and Immunogenic in Healthy Adults, by John Hennessey, Ph.D., Vice President of R&D for NovaDigm, on Monday, May 7, 2012 at 3:30pm in a session entitled “Vaccine Candidates: Preclinical and Clinical Studies.”

Date: May 7, 2012
Source: NovaDigm Therapeutics


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE